Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
120 participants in 4 patient groups, including a placebo group
There are currently no registered sites for this trial.
Central trial contact
Study Contact
Start date
Jul 11, 2018 • 6 years ago
End date
Jul 19, 2023 • 1 year and 8 months ago
Results posted
ViewMar 28, 2025 • 9 days ago
Today
Apr 06, 2025
Lead Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal